GeneNews’ ColonSentry™ Test Featured in Canadian Medical Journal

GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced an article on the Company’s first product ColonSentry™, the world’s first blood-based test to determine a person’s current risk for colorectal cancer, will appear in the January 2009 issue of The Canadian Journal of Diagnosis. This journal has a circulation of about 36,500 physicians and, according to our market research, is among the top medical journals read by family care physicians to learn about new advances in medicine. The article will be published this week in the Medical Briefs section of the journal.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.